The company is demonstrably advanced the progress of an innovative solution for cardiac amyloidosis, leveraging Attruby. Preliminary clinical results suggests potential outcomes for patients suffering by this serious https://biotech182105.blogsidea.com/48966287/bridgebio-advances-amyloidosis-therapy-using-the-therapy